NCT03841201View on ClinicalTrials.gov

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

50

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

October 27, 2022

Study Completion Date

May 2, 2023

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG

Lenvatinib

oral

DRUG

Nivolumab

iv infusion

Trial Locations (1)

30625

Hannover Medical School, Hanover

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Eisai GmbH

INDUSTRY

lead

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

OTHER